Dolutegravir Sodium Tablets Manufacturer in India

Product Overview
Key Features
Therapeutic Uses
Dosage Form Advantages

Genliva Wellness LLP develops Dolutegravir Sodium Tablets for antiretroviral therapy programs focused on long-term HIV infection management and viral suppression. The formulation is regularly incorporated into combination HIV treatment regimens requiring integrase inhibitor-based antiviral therapy.

Dolutegravir Sodium blocks HIV integrase enzymes responsible for viral DNA integration into host immune cells, interrupting the viral replication cycle. The medicine is widely utilized in first-line and maintenance antiretroviral protocols due to its strong antiviral activity and prolonged therapeutic effectiveness.

As a trusted Dolutegravir Tablets Manufacturer in India, Genliva Wellness LLP supplies antiviral pharmaceutical formulations for institutional healthcare procurement programs, government HIV treatment initiatives, pharmaceutical distributors, and regulated export markets.

Dolutegravir Sodium Tablets are formulated for integrase inhibitor-based antiviral therapy.

Anti-HIV integrase inhibitor tablet formulation
Frequently utilized in combination antiretroviral regimens
Activity against HIV viral integration pathways
Optimized oral antiviral administration profile
Manufactured under WHO GMP quality standards
Intended for long-term HIV treatment programs

This formulation is prescribed in HIV infection management and antiviral treatment protocols.

Treatment of HIV infection
Management of antiretroviral therapy regimens
Administered in viral suppression treatment programs
Utilized in long-term HIV care protocols
Targets HIV integrase enzyme activity
Frequently selected in institutional antiviral therapies

Dolutegravir Sodium Tablets deliver potent antiviral activity for HIV treatment management.

Valuable in first-line HIV therapy protocols
Frequently preferred in combination antiviral regimens
Long-acting antiviral therapeutic performance
Convenient oral antiviral treatment option
Useful in institutional HIV care programs
Maintains strong integrase inhibitor activity